Subscribe
Models
Our Products
Featured Catalog
Humanized Mouse Models
Tool Mice
Services
Drug Discovery and Development
Antibody Discovery Platform
Therapeutic Area
Resources
About Us
huNK2R(TACR2) Mouse
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
huNK2R(TACR2) Mouse
Product Name
huNK2R(TACR2) Mouse
Product ID
C002097
Strain Name
C57BL/6NCya-Tacr2tm1(hTACR2)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “huNK2R(TACR2) Mouse (Catalog C002097) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
Basic Information
Related Resource
Basic Information
Gene Name
TACR2
Gene Alias
SKR, NK2R, NKNAR, TAC2R
NCBI ID
Chromosome
Chr 10 (Human)
MGI ID
Datasheet
Strain Description
The TACR2 gene encodes tachykinin receptor 2 (also known as neurokinin 2 receptor, NK2R), a member of the G protein-coupled receptor (GPCR) superfamily that serves as a high-affinity receptor for neurokinin A (also referred to as substance K). Recent studies have shown that the TACR2/NK2R signaling pathway is closely associated with metabolic diseases such as obesity and type 2 diabetes (T2D) and plays important roles in regulating energy expenditure and appetite. NK2R agonists simultaneously promote energy expenditure and induce sustained non-aversive appetite suppression independently of the canonical leptin signaling pathway, thereby effectively reducing body weight and rapidly improving insulin sensitivity. In diet-induced obesity (DIO) mice, Ob/Ob mice, Mc4r knockout mice, and diabetic/obese cynomolgus monkey models, NK2R-selective agonists significantly reduced body weight, blood glucose, triglyceride, and cholesterol levels while improving insulin resistance, without causing any apparent severe adverse effects [1-2]. Therefore, as a single target capable of simultaneously regulating energy expenditure and appetite, NK2R represents a promising therapeutic target for metabolic diseases and provides a novel strategy for the development of precision therapies for obesity, type 2 diabetes (T2D), and related metabolic disorders.
The huNK2R(TACR2) humanized mouse was generated via gene-editing technology by replacing the sequence spanning from the start codon to the stop codon of the endogenous mouse Tacr2 gene with the corresponding sequence of the human TACR2 gene. Its primary applications include mechanistic studies of metabolic diseases such as obesity and type 2 diabetes (T2D), as well as the exploration of therapeutic strategies targeting the NK2R pathway. This model can also be used to evaluate the potential effects of related interventions on energy metabolism and appetite regulation.
Reference
Sass F, Ma T, Ekberg JH, Kirigiti M, Ureña MG, Dollet L, Brown JM, Basse AL, Yacawych WT, Burm HB, Andersen MK, Nielsen TS, Tomlinson AJ, Dmytiyeva O, Christensen DP, Bader L, Vo CT, Wang Y, Rausch DM, Kristensen CK, Gestal-Mato M, In Het Panhuis W, Sjøberg KA, Kernodle S, Petersen JE, Pavlovskyi A, Sandhu M, Moltke I, Jørgensen ME, Albrechtsen A, Grarup N, Babu MM, Rensen PCN, Kooijman S, Seeley RJ, Worthmann A, Heeren J, Pers TH, Hansen T, Gustafsson MBF, Tang-Christensen M, Kilpeläinen TO, Myers MG Jr, Kievit P, Schwartz TW, Hansen JB, Gerhart-Hines Z. NK2R control of energy expenditure and feeding to treat metabolic diseases. Nature. 2024 Nov;635(8040):987-1000.
Pavlovskyi A, Ren Y, Gestal-Mato M, Olsen OH, Schwartz TW, Gerhart-Hines Z, Liu X. Structurally defining neurokinin selectivity to improve NK2R agonists. Nat Struct Mol Biol. 2026 Jul;33(7):1086-1096.
Strain Strategy
The mouse Tacr2 gene sequence from the start codon to the stop codon was replaced with the corresponding human TACR2 gene sequence.

Figure 1. Gene editing strategy of huNK2R(TACR2) mice.
Application Area
Mechanistic research on metabolic diseases, such as obesity and type 2 diabetes (T2D);
Therapeutic strategies targeting the NK2R pathway.
Related Resource
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

